ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Formulation and evaluation of polymeric nanoparticles to improve in vivo chemotherapeutic efficacy of mangiferin against breast cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesoporous silica nanoparticles--based functional platforms for breast cancer therapy: technological advancements.Frontiers in chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mangiferin (Mgf), a naturally occurring polyphenol, can act as an apoptosis inducer for various cancer cells. Thus, it is holding the prospect of being a promising chemotherapeutic agent. However, a discrepancy between the in vitro results and in vivo observations seems to exist that apprehends its potential usefulness. The in vivo chemotherapeutic capacity of Mgf is greatly challenged because of the unfavorable pharmacokinetic credentials. The present study aims to overcome the biopharmaceutical limitations and improve the chemotherapeutic efficacy by incorporating it within nano-scale delivery system. Stable and sphere-shaped Mgf-loaded poly(lactic-co-glycolic) acid (PLGA) nanoparticles (MNPs) were formulated using the nanoprecipitation method and characterized. Further, MNPs were assessed through multiple in vitro and in vivo preclinical evaluations for their chemotherapeutic efficacy, with an ambition to improve the performance in the biological system. Sphere-shaped MNPs exhibited satisfactory drug loading and release profile. The Mgf-loaded nanoformulation also exhibited better cytotoxic potential against breast cancer cells compared to native Mgf owing to its better penetrability into cancer cells. MNPs were also found to confer superior in vivo chemotherapeutic efficacy in breast cancer-bearing mice evidenced by the reduction of tumor load. Improved anti-cancer potential of MNPs over free Mgf was also established through different bioassays. Moreover, the nanoparticles did not confer systemic toxicity to levels of concern. To conclude, the current study pleads for MNPs as a safe and efficacious tool in the fight against breast cancer for futuristic translations.
Indexed as
Identifiers
40153014What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.